Amarin's Stock Drops on Plan to Sell Heart Drug Vascepa Alone
MINYANVILLE ORIGINAL Shares of Amarin (NASDAQ:AMRN) are falling after the drug maker said it will hire a sales force to market its heart medicine derived from pure fish oil rather than partner with another company. Amarin says it is still exploring a strategic partner or outright sale of the company. Amarin says it will hire as many as 300 sales representatives to launch the drug Vascepa in the US during the first quarter of 2013. The announcement made late in the day Thursday also detailed a $100 million financing the company arranged through an investment fund. The company’s shares ...
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here